|Systematic IUPAC name
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||410.730 g·mol−1|
|Appearance||Pale yellow, translucent liquid|
|Density||0.858 g cm−3|
|Melting point||−5 °C (23 °F; 268 K)|
|Boiling point||285 °C (545 °F; 558 K) at 3.3 kPa|
|Viscosity||12 cP (at 20 °C)|
|NFPA 704 (fire diamond)|
|Flash point||110 °C (230 °F; 383 K)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Squalene is a natural organic compound originally obtained for commercial purposes primarily from shark liver oil (hence its name, as Squalus is a genus of sharks), although plant sources (primarily vegetable oils) are now used as well, including amaranth seed, rice bran, wheat germ, and olives. Yeast cells have been genetically engineered to produce commercially useful quantities of "synthetic" squalene.
All plants and animals produce squalene as a biochemical intermediate, including humans. It occurs in high concentrations in the stomach oil of birds in the order Procellariiformes. Squalene is a hydrocarbon and a triterpene, and is a precursor for synthesis of all plant and animal sterols, including cholesterol and steroid hormones in the human body.
Role in steroid synthesis
Squalene is the biochemical precursor to the whole family of steroids. Oxidation (via squalene monooxygenase) of one of the terminal double bonds of squalene yields 2,3-squalene oxide, which undergoes enzyme-catalyzed cyclization to afford lanosterol, which is then elaborated into cholesterol and other steroids.
Squalene is an ancient molecule. In plants, squalene is the precursor to stigmasterol. In certain fungi, it is the precursor to ergosterol. However, blue-green algae and some bacteria do not manufacture squalene, and must acquire it from the environment if they need it. Metabolomics has revealed that Camellia japonica leaf contains pentacyclic triterpenoid anti-inflammatory compound, lupeol which is produced from the precursor squalene.
- Two molecules of farnesyl pyrophosphate condense with reduction by NADPH to form squalene - by squalene synthase.
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
Squalene is a low density compound often stored in the bodies of cartilaginous fish such as sharks, which lack a swim bladder and must therefore reduce their body density with fats and oils. Squalene, which is stored mainly in the shark's liver, is lighter than water with a specific gravity of 0.855. Recently it has become a trend to hunt sharks to process their livers for the purpose of making squalene health capsules. Environmental and other concerns over shark hunting have motivated its extraction from vegetable sources or biosynthetic processes instead.
As a common lipid produced by sebaceous glands, squalene has a role in topical skin lubrication and protection. Toxicology studies indicate that in the concentrations used in cosmetics, squalene has low acute toxicity, and is not a significant contact allergen or irritant.
Use as an adjuvant in vaccines
Immunologic adjuvants are substances, administered in conjunction with a vaccine, that stimulate the immune system and increase the response to the vaccine. Squalene is not itself an adjuvant, but it has been used in conjunction with surfactants in certain adjuvant formulations.
An adjuvant using squalene is Seqirus' proprietary MF59, which is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory cells. It is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. It was developed in the 1990s by researchers at Ciba-Geigy and Chiron; both companies were subsequently acquired by Novartis. Novartis was later acquired by CSL Bering and created the company Seqirus. It is present in the form of an emulsion and is added to make the vaccine more immunogenic. However, the mechanism of action remains unknown. MF59 is capable of switching on a number of genes that partially overlap with those activated by other adjuvants. How these changes are triggered is unclear; to date, no receptors responding to MF59 have been identified. One possibility is that MF59 affects the cell behavior by changing the lipid metabolism, namely by inducing accumulation of neutral lipids within the target cells. An influenza vaccine using MF59 as an adjuvant was approved for use in the US in people 65 years of age and older, beginning with the 2016-2017 flu season.
A 2009 meta-analysis assessed data from 64 clinical trials of influenza vaccines with the squalene-containing adjuvant MF59 and compared them to the effects of vaccines with no adjuvant. The analysis reported that the adjuvanted vaccines were associated with slightly lower risks of chronic diseases, but that neither type of vaccines altered the rate of autoimmune diseases; the authors concluded that their data "supports the good safety profile associated with MF59-adjuvanted influenza vaccines and suggests there may be a clinical benefit over non-MF59-containing vaccines".
There have been attempts to link squalene to Gulf War Syndrome mainly due to the idea that squalene might have been present in an anthrax vaccine given to some military personnel during the 1991 Persian Gulf War. Studies found that deployed Persian Gulf War Syndrome patients are significantly more likely to have antibodies to squalene (95 percent) than asymptomatic Gulf War veterans (0 percent; p<.001). The first of these published results concludes with the following statement: "It is important to note that our laboratory-based investigations do not establish that squalene was added as adjuvant to any vaccine used in military or other personnel who served in the Persian Gulf War era." The second publication, however, links the incidence of anti-squalene antibodies and Gulf War Syndrome to five specific lots of vaccine. Furthermore, they cite results of 1999 testing by the U.S. Food and Drug Administration which found these specific lots of vaccine to contain squalene. In response to these results, a committee of the US Institute of Medicine stated that "The committee does not regard this study as providing evidence that the investigators have successfully measured antibodies to squalene", since the authors did not perform the normal scientific controls needed to show that their test was specific to anti-squalene antibodies. It has also been determined that the anthrax vaccines given to those US military personnel did not use squalene as an adjuvant. The vaccines were also tested for squalene, and none was detected with standard methods. Another method found no squalene in 37 of the 38 lots tested. One lot contained traces of squalene, at less than ten parts per billion, which is about one-thirtieth the level found in human blood. The FDA stated that this trace of squalene probably came from a fingerprint, since the oils on human skin contain enough squalene to send these extremely sensitive tests "off the chart".
A later study reported that about one in ten people have squalene antibodies in their blood, regardless of whether or not they received squalene from a vaccination. A later study confirmed this result, and also showed that vaccination with squalene-containing vaccines do not alter the levels of these naturally-occurring antibodies. A third study showed that these naturally-occurring antibodies were no more common in Gulf war veterans than in the general population.
A squalene adjuvanted influenza vaccine, Pandemrix, that was given in Scandinavia and elsewhere in Europe in 2009 may be associated with narcolepsy, a disorder of wakefulness. Incidence of this side effect was rare — just 1 in 15,000 or 1 in 50,000, depending on the country — but statistically significant. An epidemiologic analysis of safety data on MF59 seasonal and pandemic influenza vaccines showed no evidence of increased risk of vaccine adverse events of potential autoimmune origin.
The World Health Organization and the US Department of Defense have both published extensive reports that emphasize that squalene is a chemical naturally occurring in the human body, present even in oils of human fingerprints. WHO goes further to explain that squalene has been present in over 22 million flu vaccines given to patients in Europe since 1997 and there have never been significant vaccine-related adverse events.
- CID 1105 from PubChem
- Merck Index, 11th Edition, 8727
- Ernst, Josef; Sheldrick, William S.; Fuhrhop, Juergen H. (1976). "Crystal structure of squalene". Angewandte Chemie. 88 (24): 851. doi:10.1002/ange.19760882414.
- "Four synthetic biology inventions that flummox the Feds".
- Bloch, Konrad E. (1983). "Sterol, Structure and Membrane Functio". Critical Reviews in Biochemistry and Molecular Biology. 14: 47–92. doi:10.3109/10409238309102790.
- Majumder, Soumya; Ghosh, Arindam; Bhattacharya, Malay (2020-08-27). "Natural anti-inflammatory terpenoids in Camellia japonica leaf and probable biosynthesis pathways of the metabolome". Bulletin of the National Research Centre. 44 (1): 141. doi:10.1186/s42269-020-00397-7. ISSN 2522-8307.
- Wolosik K1, Knas M, Zalewska A, Niczyporuk M, Przystupa AW. The importance and perspective of plant-based squalene in cosmetology. J Cosmet Sci. 2013 Jan-Feb;64(1):59-66.
- Spanova, Miroslava & Daum, Guenther. Squalene - biochemistry, molecular biology, process biotechnology, and applications. Eur. J. Lipid Sci. Technol. 2011,000, 0000–0000 DOI:10.1002/ejlt.201100203
- Biosynthesis of Squalene from Farnesyl Diphosphate in Bacteria: Three Steps Catalyzed by Three Enzymes. Jian-Jung Pan, Jose O. Solbiati, Gurusankar Ramamoorthy, Brandan S. Hillerich, Ronald D. Seidel, John E. Cronan, Steven C. Almo, and C. Dale Poulter. ACS Central Science 2015 1 (2), 77-82 DOI: 10.1021/acscentsci.5b00115
- Pappas, A (2009). "Epidermal surface lipids". Dermato-endocrinology. 1 (2): 72–76. doi:10.4161/derm.1.2.7811. PMC 2835894. PMID 20224687.
- "Final Report on the Safety Assessment of Squalane and Squalene". International Journal of Toxicology. 1 (2): 37–56. 1982. doi:10.3109/10915818209013146.
- "Final Report on the Safety Assessment of Squalane and Squalene" (PDF). International Journal of Toxicology. 1 (2): 37–56. 1982. doi:10.3109/10915818209013146.
- Huang, Zih-Rou; Lin, Yin-Ku; Fang, Jia-You (2009). "Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology" (PDF). Molecules. 14 (1): 540–54. doi:10.3390/molecules14010540. PMC 6253993. PMID 19169201.
- Squalene-based adjuvants in vaccines, Global Advisory Committee on Vaccine Safety, World Health Organization
- Mosca, F.; Tritto, E.; Muzzi, A.; Monaci, E.; Bagnoli, F.; Iavarone, C.; O'Hagan, D.; Rappuoli, R.; De Gregorio, E. (2008). "Molecular and cellular signatures of human vaccine adjuvants". Proceedings of the National Academy of Sciences. 105 (30): 10501–6. Bibcode:2008PNAS..10510501M. doi:10.1073/pnas.0804699105. PMC 2483233. PMID 18650390.
- Kalvodova, Lucie (2010). "Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation". Biochemical and Biophysical Research Communications. 393 (3): 350–5. doi:10.1016/j.bbrc.2009.12.062. PMID 20018176.
- "FLUAD, Flu Vaccine With Adjuvant". US Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. 14 December 2017.
- Pellegrini, Michele; Nicolay, Uwe; Lindert, Kelly; Groth, Nicola; Della Cioppa, Giovanni (2009). "MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database". Vaccine. 27 (49): 6959–65. doi:10.1016/j.vaccine.2009.08.101. PMID 19751689.
- Asa, P; Wilson, R; Garry, RF (2002). "Antibodies to Squalene in Recipients of Anthrax Vaccine". Experimental and Molecular Pathology. 73 (1): 19–27. doi:10.1006/exmp.2002.2429. PMID 12127050.
- Asa, P; Cao, Y; Garry, RF (2000). "Antibodies to Squalene in Gulf War Syndrome". Experimental and Molecular Pathology. 68 (1): 55–64. doi:10.1006/exmp.1999.2295. PMID 10640454.
- Committee on Government Reform Hearings for the United States House of Representatives, October 3rd and 11th, 2000. "Accountability of DoD, FDA and BioPort Officials for the Anthrax Vaccine Immunization Program (AVIP)."
- Sox, Harold C.; Fulco, Carolyn; Liverman, Catharyn T. (2000). Gulf War and health. Washington, D.C: National Academy Press. p. 311. ISBN 978-0-309-07178-9.
- Del Giudice, G.; Fragapane, E.; Bugarini, R.; Hora, M.; Henriksson, T.; Palla, E.; O'Hagan, D.; Donnelly, J.; et al. (2006). "Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene". Clinical and Vaccine Immunology. 13 (9): 1010–3. doi:10.1128/CVI.00191-06. PMC 1563566. PMID 16960112.
- Gulf War illnesses: questions about the presence of squalene antibodies in veterans can be resolved, United States General Accounting Office 1999
- Jess Henig Innoculation Misinformation: Claims that the swine flu vaccine is dangerous range from overblown to false Newsweek Oct 19, 2009
- Spanggord, R; Wu, B; Sun, M; Lim, P; Ellis, WY (2002). "Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed". Journal of Pharmaceutical and Biomedical Analysis. 29 (1–2): 183–93. doi:10.1016/S0731-7085(02)00009-2. PMID 12062677.
- Spanggord, Ronald J.; Sun, Meg; Lim, Peter; Ellis, William Y. (2006). "Enhancement of an analytical method for the determination of squalene in anthrax vaccine adsorbed formulations". Journal of Pharmaceutical and Biomedical Analysis. 42 (4): 494–9. doi:10.1016/j.jpba.2006.04.009. PMID 16762524.
- The Facts on Squalene FDA 2005
- Matyas, G; Rao, M; Pittman, PR; Burge, R; Robbins, IE; Wassef, NM; Thivierge, B; Alving, CR (2004). "Detection of antibodies to squalene III. Naturally occurring antibodies to squalene in humans and mice". Journal of Immunological Methods. 286 (1–2): 47–67. doi:10.1016/j.jim.2003.11.002. PMID 15087221.
- Phillips, Christopher J.; Matyas, Gary R.; Hansen, Christian J.; Alving, Carl R.; Smith, Tyler C.; Ryan, Margaret A.K. (2009). "Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness". Vaccine. 27 (29): 3921–6. doi:10.1016/j.vaccine.2009.03.091. PMID 19379786.
- Yox, Susan B.; Offit, Paul A. (2017). "Stories of Science Gone Wrong: Paul Offit on His New Book". Medscape.
- Nohynek, H.; et al. (2012). "AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland". PLOS ONE. 7 (3): e33536. Bibcode:2012PLoSO...733536N. doi:10.1371/journal.pone.0033536. PMC 3314666. PMID 22470453.
- Swedish Medical Products Agency (2011). "Report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy" (PDF). Euro Surveill. 16 (26).
- Asano, KG; Bayne, CK; Horsman, KM; Buchanan, MV (2002). "Chemical composition of fingerprints for gender determination". Journal of Forensic Sciences. 47 (4): 805–7. doi:10.1520/JFS15460J. PMID 12136987.